Coherus Oncology (CHRS) Non-Current Debt: 2016-2025
Historic Non-Current Debt for Coherus Oncology (CHRS) over the last 10 years, with Sep 2025 value amounting to $37.0 million.
- Coherus Oncology's Non-Current Debt rose 0.93% to $37.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.0 million, marking a year-over-year increase of 0.93%. This contributed to the annual value of $36.7 million for FY2024, which is 85.11% down from last year.
- As of Q3 2025, Coherus Oncology's Non-Current Debt stood at $37.0 million, which was up 0.24% from $36.9 million recorded in Q2 2025.
- In the past 5 years, Coherus Oncology's Non-Current Debt registered a high of $246.5 million during Q4 2023, and its lowest value of $36.5 million during Q2 2024.
- Its 3-year average for Non-Current Debt is $116.1 million, with a median of $37.0 million in 2025.
- Its Non-Current Debt has fluctuated over the past 5 years, first skyrocketed by 323.39% in 2022, then slumped by 85.14% in 2024.
- Coherus Oncology's Non-Current Debt (Quarterly) stood at $75.5 million in 2021, then spiked by 225.09% to $245.5 million in 2022, then rose by 0.41% to $246.5 million in 2023, then slumped by 85.11% to $36.7 million in 2024, then climbed by 0.93% to $37.0 million in 2025.
- Its Non-Current Debt was $37.0 million in Q3 2025, compared to $36.9 million in Q2 2025 and $36.8 million in Q1 2025.